Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia. Br J Haematol 2010 Aug;150(4):480-1
Date
05/12/2010Pubmed ID
20456357DOI
10.1111/j.1365-2141.2010.08218.xScopus ID
2-s2.0-77955163811 (requires institutional sign-in at Scopus site) 3 CitationsAuthor List
Olteanu H, Harrington AM, Ramirez S, Kroft SH, Hari PAuthors
Parameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of WisconsinAlexandra M. Harrington MD Professor in the Pathology department at Medical College of Wisconsin
Steven Howard Kroft MD Chair, Professor in the Pathology department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AlemtuzumabAntibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Antineoplastic Agents
Drug Administration Schedule
Female
Humans
Leukemia, Large Granular Lymphocytic
Middle Aged
Purpura, Thrombocytopenic, Idiopathic